US2014271684A1PendingUtilityA1
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
Est. expiryJul 23, 2027(~1 yrs left)· nominal 20-yr term from priority
A61K 2039/55516A61K 2039/55522A61K 2039/505A61K 39/39558A61P 35/00A61K 38/193A61K 39/3955A61K 40/4271A61K 40/4245A61K 40/11A61K 2239/57A61K 2239/38A61K 39/001136
70
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.
Claims
exact text as granted — not AI-modified1 . A method of cancer immunotherapy comprising: administering a combination of a cytokine-expressing cellular immunotherapy and an antibody that specifically binds to human Programmed Death 1 (anti-PD-1) to a subject with cancer, wherein administration of the combination results in enhanced therapeutic efficacy relative to administration of the cytokine-expressing cellular immunotherapy or the anti-PD-1 antibody alone.
2 - 55 . (canceled)Join the waitlist — get patent alerts
Track US2014271684A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.